Gosset Molecular Classification
Radioisotope, Beta-emitter, Gamma-emitter
Other Names
Lutetium-177 Beta Particles, 177Lu Beta Emission, Lu-177 Beta Decay, Beta Radiation from Lutetium-177
Disease Roles
Beta Radiation Emission from Lutetium-177 Overview
Lutetium-177 (Lu-177) is a radioactive isotope used in nuclear medicine for targeted radionuclide therapy (TRT). Its therapeutic effect is primarily due to the emission of beta-minus particles, which induce DNA damage and cell death in targeted cells. Lu-177 also emits gamma photons, enabling imaging and dosimetry. It is used in radioligand therapies like Lu-177 DOTATATE and Lu-177 PSMA ligands for treating neuroendocrine tumors and prostate cancer, respectively.
Mechanism of Action
Emitted beta-minus particles cause DNA damage within target cells, leading to cell death.
Biological Functions
DNA damage induction
Cell death induction
Targeted radiotherapy
Imaging (gamma emissions)
Disease Associations
Cancer Therapy
Neuroendocrine tumors
Prostate cancer
Bone metastases
Hematological malignancies
Safety Considerations
- Radiation exposure
- Off-target toxicity
- Myelosuppression
- Nephrotoxicity
Interacting Drugs
Lu-177 DOTATATE
Associated Biomarkers
| Biomarker |
|---|
| Somatostatin receptor expression (for Lu-177 DOTATATE) |
| Prostate-specific membrane antigen (PSMA) expression (for Lu-177 PSMA ligands) |